Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes in Advanced Melanoma Patients.

[1] A. Mackensen, G. Carcelain, S. Viel et al., “Direct evidence to support the immunosurveillance concept in a human regressive melanoma,” The Journal of Clinical Investigation, vol. 93, no. 4, pp. 1397-1402, 1994. [OpenAIRE]

[2] C. Jandus, D. Speiser, and P. Romero, “Recent advances and hurdles in melanoma immunotherapy,” Pigment Cell & Melanoma Research, vol. 22, no. 6, pp. 711-723, 2009.

[3] F. S. Hodi, S. J. O'Day, D. F. McDermott et al., “Improved survival with ipilimumab in patients with metastatic melanoma,” The New England Journal of Medicine, vol. 363, no. 8, pp. 711-723, 2010.

[4] C. Robert, L. Thomas, I. Bondarenko et al., “Ipilimumab plus dacarbazine for previously untreated metastatic melanoma,” The New England Journal of Medicine, vol. 364, no. 26, pp. 2517-2526, 2011.

[5] C. Robert, J. Schachter, G. V. Long et al., “Pembrolizumab versus ipilimumab in advanced melanoma,” The New England Journal of Medicine, vol. 372, no. 26, pp. 2521-2532, 2015.

[6] C. Robert, G. V. Long, B. Brady et al., “Nivolumab in previously untreated melanoma without BRAF mutation,” The New England Journal of Medicine, vol. 372, no. 4, pp. 320- 330, 2015.

[7] L. M. Muul, P. J. Spiess, E. P. Director, and S. A. Rosenberg, “Identification of specific cytolytic immune responses against autologous tumor in humans bearing malignant melanoma,” Journal of Immunology, vol. 138, pp. 989-995, 1987.

[8] S. A. Rosenberg and N. P. Restifo, “Adoptive cell transfer as personalized immunotherapy for human cancer,” Science, vol. 348, no. 6230, pp. 62-68, 2015. [OpenAIRE]

[9] M. J. Besser, R. Shapira-Frommer, A. J. Treves et al., “Clinical responses in a phase II study using adoptive transfer of shortterm cultured tumor infiltration lymphocytes in metastatic melanoma patients,” Clinical Cancer Research, vol. 16, no. 9, pp. 2646-2655, 2010.

[10] M. E. Dudley, J. R. Wunderlich, P. F. Robbins et al., “Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes,” Science, vol. 298, no. 5594, pp. 850-854, 2002.

[11] M. E. Dudley, C. A. Gross, R. P. Somerville et al., “Randomized selection design trial evaluating CD8+−enriched versus unselected tumor-infiltrating lymphocytes for adoptive cell therapy for patients with melanoma,” Journal of Clinical Oncology, vol. 31, no. 17, pp. 2152-2159, 2013.

[12] E. Ellebaek, T. Z. Iversen, N. Junker et al., “Adoptive cell therapy with autologous tumor infiltrating lymphocytes and lowdose Interleukin-2 in metastatic melanoma patients,” Journal of Translational Medicine, vol. 10, no. 1, p. 169, 2012.

[13] S. Pilon-Thomas, L. Kuhn, S. Ellwanger et al., “Efficacy of adoptive cell transfer of tumor-infiltrating lymphocytes after lymphopenia induction for metastatic melanoma,” Journal of Immunotherapy, vol. 35, no. 8, pp. 615-620, 2012.

[14] M. J. Besser, R. Shapira-Frommer, O. Itzhaki et al., “Adoptive transfer of tumor-infiltrating lymphocytes in patients with metastatic melanoma: intent-to-treat analysis and efficacy after failure to prior immunotherapies,” Clinical Cancer Research, vol. 19, no. 17, pp. 4792-4800, 2013.

[15] B. Dréno, J. M. Nguyen, A. Khammari et al., “Randomized trial of adoptive transfer of melanoma tumor-infiltrating lymphocytes as adjuvant therapy for stage III melanoma,” Cancer Immunology, Immunotherapy, vol. 51, no. 10, pp. 539-546, 2002.